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Quantitative imaging by pixel-based contrast-enhanced 
ultrasound reveals a linear relationship between synovial 
vascular perfusion and the recruitment of pathogenic IL-17A-
F+IL-23+CD161+ CD4+ T helper cells in psoriatic arthritis joints 
 
Abstract To develop quantitative imaging biomarkers of synovial tissue perfusion by pixel-based contrast-
enhanced ultrasound (CEUS), we studied the relationship between CEUS synovial vascular perfusion and the 
frequencies of pathogenic T helper (Th)-17 cells in psoriatic arthritis (PsA) joints. Eight 
consecutive patients with PsA were enrolled in this study. 
Gray scale CEUS evaluation was performed on the same joint immediately after joint aspiration, by automatic 
assessment perfusion data, using a new quantification approach of pixelbased analysis and the gamma-variate 
model. The set of perfusional parameters considered by the time intensity curve includes the maximum value 
(peak) of the signal intensity curve, the blood volume index or area under the curve, 
(BVI, AUC) and the contrast mean transit time (MTT). The direct ex vivo analysis of the frequencies of SF 
IL17AF+CD161+IL23+ CD4+ T cells subsets were quantified by fluorescence-activated cell sorter (FACS). In cross-
sectional analyses, when tested for multiple comparison setting, a false discovery rate at 10%, a common 
pattern of correlations between CEUS Peak, AUC (BVI) and MTT parameters with the IL17A-F+IL23+ - IL17A-F+ 
CD161+ - and IL17AF+CD161+IL23+ CD4+ T cells subsets, as well as lack of correlation 
between both peak and AUC values and both CD4+T and CD4+IL23+ Tcells, was observed. The pixel-based CEUS 
assessment is a truly measure synovial inflammation, as a useful tool to develop quantitative imaging 
biomarker for monitoring target therapeutics in PsA. 
 
Introduction 
Psoriatic arthritis (PsA) is a systemic immune-mediated disease, characterized by enthesitis, 
synovitis, and osteitis, associated to skin psoriasis, with marked clinical heterogeneity [1, 2] linked to 
PsA-specific, immune-related susceptibility risk loci such as HLA-B, PTPN22, TNFAIP3, and IL23R [3, 
4]. 
The activation of interleukin (IL)-23 pathway and induction of IL-17 cytokine axis (IL-17A; IL-17F; IL-
22) have been identified as important immunopathological mechanisms in PsA joint inflammation, 
involving both the innate and adoptive immune response [5–7]. 
The upregulation of the pro-inflammatory IL-17 axis is supported by both the upregulation of the 
pro-inflammatory cytokines, especially IL-1β, IL-6 and IL-17, IL-21, IL-22 and IL-23 in synovial tissue 
(ST), and synovial fluid (SF) [8–12], and by the expansion either of CD4+ T helper cells, which produce 
IL-17A and IL-17F (Th17) [12–18] or CD8+IL-17-producing T cells [19] in the PsA joints. 
Th17 are memory cells which display functional properties distinct from other CD4+ Th cells and 
express distinctive Th17 molecules, such as the lineage-defining transcription factor retinoid acid-
related orphan receptor gamma T (RORγt), the c-type lectin CD161 [20], the IL-23Rp19, the 
chemokine receptor 6 CCR6), and CCR4 [21, 22]. Either the  levels of IL-17, or the frequencies of 
CD4+ Th17+, or CD8+ IL-17+ T cells in the peripheral circulation, as in SF, showed a significant 
relation to the systemic disease activity, both at the onset and the progression of PsA and RA [10, 
19]. 
New investigational anti-interleukin chimeric and monoclonal antibody biologic agents targeting the 
Th17- IL-23 pathway (ustekimumab, secukinumab, ixekizumab, tildrakizumab, and guselkumab) and 
the bispecific TNF/IL-17 (bimekyzumamb)monoclonal antibodies, are under development in PsA [23, 
24]. 
The introduction of targeted PsA therapeutics makes urgent the validation and application of 
quantitative imaging biomarkers for the assessment of the response to treatment. 
SonoVue, a second-generation pulse-inversion harmonic imaging contrast-enhanced ultrasound 
(CEUS) medium consists of inert gas-filled microbubbles, embedded by a phospholipid membrane, 
the size <10 μm, characteristics that prevent them from leaving the vascular system. So it is a long 
persistence, pure Bblood pool contrast agent^, unlike standard computed tomography—and 
magnetic resonance imaging—contrast agents. The analysis of time-intensity curves of dye kinetics 
allows a dynamic real-time imaging [25], thus making it favorable clinic-based tool to assess 
functional vascular parameters, such as perfusion and relative blood volume [26]. However, the 
distinctive pathophysiology of PsA synovitis, characterized since the disease onset, by a rapid 
vascular growth and tortuous blood vessels at the synovio-entheseal complex [27, 28], with 
inhomogeneous distribution, throughout the relapsing course of the disease [29], makes difficult the 
quantitative imaging assessment of synovitis by video intensity data. Hence, to develop quantitative 
imaging biomarkers for the automatic assessment of synovial tissue perfusion, we adopted a novel 
quantification approach of pixel-based analysis, that derives kinetic parameters for each pixel within 
the synovial area. [30]. 
The main goal of the study was the assessment of the relationship of CEUS perfusion kineticswith 
the direct ex vivo SF analysis of pro-inflammatory Th17 cells subset in a cohort of PsA patients with 
active synovitis. 
The pixel-based CEUS reveals a linear relationship between synovial vascular perfusion and the 
recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in PsA joints. 
 
Material and methods 
 
Patients 
Eight consecutive patients who fulfilled the Classification of Psoriatic ARthritis (CASPAR) criteria were 
enrolled in this study [31]. The clinical and demographic characteristics of PsA patients are reported 
in Table 1. SF samples were obtained from patients with active knee arthritis and SF effusion. In 
particular, the study of Tcell phenotypes was carried out in SF from eight PsA patients. The study was 
approved by the local Ethic Committee of the University Hospital of Padova (Italy) (number 52723; 
October 11, 2010), and written informed consent was obtained from each participant in accordance 
with the principles outlined in the Declaration of Helsinki, after being informed about the intent and 
the methodology of the study. 
 
PB and SF mononuclear cell preparation 
SF samples were collected from the swollen knees, centrifuged at 1000×g to remove cells and debris; 
the SF samples were analyzed for total white blood cell (WBC) count (WBC/μl). PB mononuclear cells 
(PBMC) and synovial fluid mononuclear cells (SFMC) were isolated from the PB and SF by Ficoll-
Paque Plus (GE Healthcare) density gradient centrifugation. Isolated mononuclear cells were washed 
twice and adjusted to 0.5–1 × 106 cells/100 μl for immunostaining. 
 
Flow cytometry analysis 
Mononuclear cells were treated for 30 min at room temperature with commercially available FITC-, 
PE-, or PE-Cy5-conjugated monoclonal antibody (mAb): anti-CD4 (Becton–Dickinson Biosciences, 
Italy), anti-IL23R (R&D Systems Inc., Minneapolis, MN, USA), and anti-IL-17 (R&D Systems); anti-
CD161 (Becton–Dickinson Biosciences, Italy). FITC-, PE-, or PE-Cy5-conjugated isotype-matched 
mouse mAb was used to set the fluorescence background (IgG1 and IgG2a, BD Pharmigen). 
Appropriate isotype controls and fluorescence minus one (FMO) controls were used to assign gates. 
Expression of the cytoplasmic cytokine was evaluated as previously described [15]. CD4+ T cells were 
gated with two different approaches: physical characteristic of cells and expression of CD4 in the 
area of lymphocytes to identify the T helper cells. Fluorescence-activated cell sorter (FACS) analysis 
was assessed as previously described, briefly, 5 × 105 cells were acquired on FACSCalibur 6 analyzer 
(Becton–Dickinson) and data processed by DIVA software program (Becton–Dickinson Biosciences, 
Italy). To evaluate whether differences between peaks were statistically significant with respect to 
controls, the Kolmogorov-Smirnov test was used. 
 
Gray scale CEUS evaluation 
Gray scale CEUS evaluation was performed on the same joint immediately after joint aspiration. 
Before contrast-enhanced study, gray scale US examination was performed with a linear 7.5–13 MHz 
array transducer by experienced sonographers. Standardized anatomic guidelines of the scan in 
three recesses of the knee—superpatellar recess (SPR) and lateral and medial parapatellar recesses 
(LPPR and MPPR)—were used [32]. SPR was evaluated by scanning the zone between the prefemoral 
(posterior  suprapatellar) fat pad and the upper margin of the femoral cartilage (supine position, 
knee joint extended, and bicipes femoris at rest). At the level of LPPR and MPPR, the vertical edge 
along the lateral and medial margins of the knee cap (bicipes femoris contracted) was identified by 
scanning. 
Contrast-enhanced US examinations were performed by means of US apparatus (Hitachi HI Vision 
Ascendus; Hitachi Medical Systems Europe Sumpfstrasse 13, CH-6300 Zug), which was specifically 
designed for sonographic examinations with a contrast agent. A contrast agent composed of sulfur 
hexafluoride-filled microbubbles (SonoVue, Bracco International B.V., Amsterdam, Nederlands) was 
used. 
Hitachi’s wideband pulse inversion contrast harmonic imaging (dCHI-W) allows the modulation of 
the phase and transmitted frequency range between pulses. Advantages include significantly 
improved lateral and contrast resolution, without compromising axial resolution. Frequency 
modulation provides greater sensitivity at depth, compared with conventional harmonic imaging. All 
patients gave their informed consent for the use of contrast agent. A 4.8-mL bolus of contrast agent 
was injected into a peripheral vein and was followed by an injection of 10 mL of physiologic saline 
solution. 
Immediately after the injections, the synovial tissue under examination was scanned with a frame 
rate of 15 frames per second. The transducer was kept in a fixed position to highlight all the phases 
of enhancement. The beam focus was placed at the level of the synovial proliferation or immediately 
below it, and beam gain was set at the minimum level. The apparatus in question affords the 
recording and filing of the images in digital format, and all the dynamic phases of the examination 
performed during 60 s were saved using this system. 
 
Pixel-wise quantitative analysis of CEUS data 
CEUS quantification at the pixel level has been shown to be more effective than region of interest 
(ROI)-based approaches in the characterization of different perfusion patterns in arthritis subtypes 
[30]. Moreover, the heterogeneity of CEUS kinetics makes the gamma-variate model insufficient to 
fully describe the behavior of the tracer, whose time appearance cannot be modeled as a flow any 
more, appearing as a trapping. Thus, we modeled the perfusion data derived by CEUS with the single 
recirculation component model (SCR) [33], by adding to the gamma-variate function an additional 
component of the integral of the gamma, that represents this apparent trapping of the microbubbles 
in the microvascular areas of significantly delayed synovial flow [34]: 
 
𝑐𝑆𝐶𝑅(𝒑, 𝑡) = 𝑐𝑔𝑎𝑚𝑚𝑎(𝒑, 𝑡) + 𝑐𝑠𝑙𝑜𝑤(𝒑, 𝑡)      𝑡 ≥ 𝑡0 
𝑐𝑔𝑎𝑚𝑚𝑎(𝒑, 𝑡) =  𝑎0 ∙ (𝑡 − 𝑡0)
𝛼 ∙ 𝑒
−
𝑡−𝑡0
𝛽    𝑡 ≥ 𝑡0 
𝑐𝑠𝑙𝑜𝑤(𝒑, 𝑡) = 𝑎1 ∫ 𝑐𝑔𝑎𝑚𝑚𝑎(𝒑, 𝜏)𝑑𝜏
𝑡
𝑡0
  𝑡 ≥ 𝑡0 
 
where 𝒑 =[𝑎0, 𝛼, 𝑡0 , 𝛽, 𝑎1]  is the vector of the model parameters 
After linearizing the ultrasound log-compressed data as in [35], we solved the model for each element 
of the image (i.e., pixel-wise approach) with a Bayesian approach [36], deriving the complete 
distribution in the synovia of several perfusion parameters. These include the shape parameters of 
the perfusion model, the contrast mean transit time (MTT), and the blood volume index (BVI), as 
reported in Fig. 1. In order to describe the heterogeneity of distinct synovial flows as well as the 
presence of small areas of characteristic flow patterns of physiopathology significance, the 
distribution of each parameter over all pixels is summarized by four statistical descriptors: mean, 
standard deviation, 25th percentile, and 75th percentile. This allows us to explore the importance of 
both the global perfusion patterns in the synovia and their variability. In particular, the distribution 
percentiles return informationon the areas of the synovia characterized by the lowest or highest 
values of the parameters of interest, that can be important in case of localized foci of inflammation 
(Fig. 2). 
Statistical analysis 
To verify the relationship between the noninvasive imaging perfusion patterns and the local levels in 
the synovia of Th17 cells, we evaluated the Spearman’s correlation coefficient between the 
parameters derived from the quantitative analysis of CEUS data and the frequencies of CD4+ T cell 
subsets. In order to accommodate for the scarcity of data, p values of the correlations were 
computed using permutation test. 
Given the high number of correlations to be tested and the small sample size, we also need to adjust 
the statistical significance considering multiple comparison. However, the Bonferroni [35] or the 
Holm-Bonferroni corrections have been shown to be too conservative in many settings (such as the 
one presented in this paper): we thus applied the false discovery rate (FDR) method [37] to control 
the amount of Type I error, setting the amount of FDR to 10%. In any case, in order to account for 
possible Type II error, we also report the estimated p values for single test. 
 
Results 
The dot plot mean and standard deviation of the frequencies of CD4+ T cell subsets are reported in 
Fig. 3, the upper and bottom panel, respectively. CEUS evaluation The significant values of CEUS 
correlations are reported in Table 2 and Supplementary Table. Single comparison test showed 
significant correlation between CD4+ IL17AF+IL23+ CD161+ T cell subset and heterogeneity of the 
time to peak in the synovium (rho = 0.74, p < 0.05), with the 25th percentile of MTT (rho = −0.85, p < 
0.01) and with the 75th percentile of BVI (rho = 0.80, p < 0.05). When tested for multiple comparison 
setting a FDR at 10%, only MTT resulted significant, with BVI being close to significant (alpha = 0.12) 
(Table 2). 
The correlations between CEUS parameters and the distinct T cell subtypes studied by FACS analysis 
are reported in Supplementary Table, showing the lack of correlation between both peak and AUC 
(BVI) values and both CD4+ and CD4 + IL23+ T cells subset, which show correlations with the 
heterogeneity of T peak and BVI. MTT shows a positive relation with CD4+ T cell frequency. 
On the contrary, there is a common pattern of correlations between CEUS Peak, AUC (BVI), and MTT 
parameters with the IL17A-F+IL23+ - IL17A-F+CD161+ - and IL17AF+CD161+IL23+ - CD4+ T cells 
subsets. Interestingly, all these CD4+ T cell subsets show negative correlations with MTT. 
 
Discussion 
The validation and application of quantitative imaging biomarkers is critical for the early assessment 
of the patient’s response to treatment. Advanced tracer development, image acquisition, and image 
analysis have been used to produce quantitative biomarkers of pathophysiology [38]. Noninvasive 
and mini-invasive imaging measurement of angiogenesis plays an emerging role in both tumor and 
joint pathologies [39, 40]. The real-time imaging, the high-spatial resolution, and the low costs 
represent the main advantages of CEUS, compared to other imaging modalities. However, a major 
drawback to develop quantitative imaging biomarkers for PsA by the conventional CEUS method is 
the heterogeneity of the distribution of the level of synovial enhancement that may affect the 
accurate quantification of synovial perfusion over the entire synovial area. In this study, we 
implemented the automatic assessment of the video intensity data with a new quantification 
approach of pixel-based analysis [30]. 
Unlike the conventional region of interest (ROI), pixel level analysis allows one to produce 
parametric maps of the same spatial resolution as the original CEUS image, as well as provides the 
localization of perfusion patterns and the evidence of kinetics differences [30]. The gamma-variate 
model of kinetic analysis was adopted, which is a more general, flexible, and physiological version of 
the traditional mono-exponential model, which already allowed to devise the relation between 
microvascular density and CEUS refilling time [32]. Nevertheless, the heterogeneity of CEUS kinetics 
as that observed in PsA synovitis [30] makes the gamma-variate model insufficient to fully describe 
the behavior of the tracer during the scan time length. In fact, by increasing the resistance to 
synovial vessel flow, the passage of the microbubbles through the highly irregular architecture of 
neoformed capillary network is slowed down, causing either the prolongation of the refilling time, or 
failure to identify the washout within the experimental time of the CEUS examination. So, it is not 
possible to model it as a flow any more, but it appears as a trapping. To obtain a comprehensive 
description of the synovial microbubble behavior in the pixel-based analysis, we modeled the 
perfusion data derived by CEUS, with the single recirculation component model, by adding to the 
gammavariate function an additional component of the integral of the gamma. This model 
represents the apparent trapping of the microbubbles in the microvascular areas of significantly 
delayed synovial flow [33, 34]. 
In the arthritis joints, the complex interplay between IL-1β, IL-6, and IL-23 cytokines results in the 
specification of proinflammatory T helper cells [41–43]. Pathogenic CD4+Th17 cells were already 
characterized ex vivo and in vitro in PsA  joints, by both the membrane expression of IL-17A, IL-6Rα, 
IL-22, IL-23p19R, INF-γ, CD161, CCR4, and CCR6, and the intracellular expression of IL17A, IL-22, 
RORCγ, JAK2, and STAT3 [10, 14, 15]. 
Since the presence in Th17 cells in either peripheral circulation, synovial fluid and synovial tissue, 
they can represent a credible immunopathological indicator of the PsA inflammatory process. In a 
translational approach to identify quantitative biomarkers of synovial angiogenesis, we compared 
the assessment of CEUS synovial perfusion with CD4+ T helper cell at the site of joint inflammation. 
To this end, a direct ex vivo FACS analysis of Th17 cell phenotypes was performed, by studying 
untouched freshly isolated SF-MNC of PsA patients, since the in vitro-cultured PMA and ionomycin-
stimulated CD4+ T cells do not necessarily reflect the natural levels of cytokine-secreting cells [15]. 
The key finding of the cross-sectional study is the linear relationship between CEUS perfusion kinetic 
and frequency of pathogenic Th17 cellular immigration in the joints of patients affected by PsA. The 
single and multiple comparison statistical analysis, using the permutation test and false discovery 
rate method [35, 37], suggests the reliability of the association between Th17 cells and Peak, MTT, 
or AUC, against the simply bystander effect of passive blood inflow of T cells in the joint cavity. The 
results of the study may improve the knowledge of the pathophysiology of PsA synovitis, since the 
pathogenic functional properties already shown by Th17 cells in arthritis joints [44, 45]. Indeed, Th17 
cells exhibited the ability to activate synovial fibroblasts, to induce IL-6, IL-8, and tissue destructive 
enzyme matrix metalloproteinase-1 and -3, and to survive and persist in the inflamed and hypoxic 
joint [10, 16, 46, 47]. 
The CD161, a c-type lectin, also expressed by natural killer cells (NK) and NK- T cells, interacts with 
the acid sphingomyelinase (ASM, ceramide), a lipid hydrolase [47, 48] by inducing Th17 cells 
proliferation [48], and mediating chemotactic-independent trans-endothelial migration of human T 
cells [49]. 
The close relationship between Th17 frequencies in PsA joints and the accurate imaging 
quantification of synovial microvascular perfusion, both of which represent objective measures of 
joint inflammation, may reflect the link between the intensity synovitis and the dynamic process of 
endothelial interaction and transmigration of the helper memory T cells in PsA joints. PDUS 
examination was already shown to be an effective diagnostic tool in early PsA and psoriasis patients, 
also allowing the detection of subclinical synovitis [50, 51]. In pioneer study in RA affected patients, 
synovial PDUS scores were found associated to the frequency of total IL-17 producing SF CD4+ T 
cells, after in vitro stimulation [52]. Recently, an elegant study in early RA demonstrated the 
relationship between quantitative assessment of power Doppler area and histologically determined 
synovial vascular area. Notably, large- and medium-sized vessels contributed for over 90% to the 
overall vascular area [53]. Instead, the limitations by the PDUS method at slow blood flow velocities 
and in small blood volumes vessels, Sonovue C agent, that follows the distribution kinetics of red 
blood cells can also refill the distal capillary network, allowing the accurate quantitative assessment 
of the whole synovial tissue microvascular flow. CEUS, compared with the unenhanced PDUS 
method, was indeed found to improve the detection of intra-articular vascularity either in RA [54], or 
PsA [55], or spondyloarthritis (SpA) sacroiliitis [56], and PsA enthesitis [57], as well as to be related to 
synovial vascular density in PsA [32]. Until now, the interrelationship between inflammation and 
angiogenesis in PsA synovitis, and the molecular mechanism of altered vascular morphology [54, 58], 
are not well understood. The proangiogenic activity of IL-17 has been well documented in arthritis 
and tumors [59, 60], as IL-17 can up-regulate the constitutive release of angiogenesis factors by 
synovial fibroblasts [12, 61, 62] and, in synergy with TNF-α, can induce endothelial migration and 
invasion [63]. Notably, by studying the anti-angiogenic action of both systemic and local TNFblocking 
treatment in PsA [64], a selective depletion of the immature microvasculature was described during 
early RA disease [65]. That was also reflected by the distinct intrasynovial spatial configuration of the 
capillary network in response to TNF-blocking therapy in RA and PsA joints [55, 66]. These findings 
may indicate the potential advantage for a therapeutic targeting a selective microvascular district. 
The field of vascular-targeted therapeutics for the treatment of arthritis, by targeting the antigens 
specifically expressed in the micro-vasculature, is still in preclinical phase [40]. The ultrasound-based 
molecular imaging by the use of the Bnext generation^ of microbubble-mediated ultrasound 
therapy, to bind and deliver drugs to target-specific sites [67–69], is rapidly expanding. In this view, 
the development of quantitative perfusion biomarkers of synovial angiogenesis is becoming of 
increasingly importance. In conclusion, the linear relationship between the PEAK, time of PEAK, and 
AUC of contrast-signal intensity values of synovial perfusion and the frequencies of CD161+IL-17+IL-
23+ CD4+ Th17 cells in the joints of patients affected by active PsA synovitis, indicating that pixel-
based CEUS assessment truly measures synovial inflammation in the highly heterogenous 
microvascular environment of PsA joints, as a useful tool to develop quantitative imaging biomarker 
for monitoring target therapeutics in PsA. 
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Tab. 1  
Clinical and demographic characteristics of psoriatic arthritis patients included in the study. PsA 
psoriatic arthritis, n number, SD standard deviation, DMARDs disease-modifying antirheumatic 
drugs, ETN etanercept, PDN prednisolone, aDaily prednisolone dose ≤10 mg 
 
Clinical and demographic characteristics of psoriatic PsA patients  
Clinical  and demographic characteristics Values 
Patient numbers 8 
Female, n (%) 2 (25) 
Patient age, years, mean ± SD 52.75 ± 15.97 
Disease duration, years, mean ± SD 7.54 ± 7.73 
Gonarthritis duration, years, mean ± SD 7.54 ± 7.37 
VES mm/h (m±DS) 19.37±12.27 
PCR mg/L (m±DS 3.76±2.67 
N° Tender jonts 28 (m±DS)  1.87±0.99 
N° Swollen Joints 28 (m±DS) 1.87±0.99 
GH status 0-100 (m±DS) 76.25±13.02 
DAS28-PCR (m±DS) 3.59±0.56 
PASI (m±DS) 1.75±1.97 
Systemic treatment at study entry   
DMARDs, n (%) 2 (25) 
ETN, n (%)  2 (25) 
PDN, n (%) 1 (12.5) 
 
PsA psoriatic arthritis, DMARDs disease-modifying antirheumatic drugs, ETN etanercept, PDN prednisolone 
 
Tab. 2  
Correlations between the distinct contrast-enhanced ultrasound parameters (CEUS) (Spearman’s 
correlation) and the frequencies of CD4+ IL17A IL17F+ CD161+ IL23+ T cells subset in synovial fluid of 
PsA patients, as detected by FACS analysis. Only significant values are reported, with their single 
comparison p-value and their multiple comparison alpha-value. 
 
  
Correlation between CEUS perfusion parameters and frequencies of   
 CD4+ IL17A-IL17F+ CD161+ IL23+ T cells synovial fluid of PsA  
Statistical descriptors of CEUS 
perfusion parameters 
Single comparison 
test (p<0.05) 
Multiple 
comparison FDR 
test (alpha<0.1) 
P
 P
 E
A
K
 Mean n.s. n.s. 
Heterogeneity  
(St. Dev.) 
n.s. n.s. 
25 perct n.s. n.s. 
75 perct 0.74 (0.02) n.s. 
M
T
T
 
Mean n.s. n.s. 
Heterogeneity  
(St. Dev.) 
n.s. n.s. 
25 perct -0.85 (0.005) -0.85 (0.065) 
75 perct n.s. n.s. 
B
V
I 
(A
U
C
) Mean n.s. n.s. 
Heterogeneity  
(St. Dev.) 
n.s. n.s. 
25 perct n.s. n.s. 
75 perct 0.80 (0.02) 0.80 (0.12) 
Tab. Suppl  
Correlations between the different contrast-enhanced ultrasound parameters (CEUS) (Spearman’s correlation) and the frequencies of different CD4+ T cells 
subsets in synovial fluid of psoriatic arthritis patients, as detected by FACS analysis. Only significant values are reported, with their single comparison p-
value and their multiple comparison alpha-value. 
  
  
CD4+ CD4+ IL17A-IL17F+ CD4+ IL23+ 
CD4+ IL17A-IL17F+ 
IL23R+ 
CD4+ IL17A-IL17F+ 
CD161+ 
CD4+ IL17A-IL17F+ 
CD161+ IL23R+ 
Statistical descriptors 
of CEUS perfusion 
parameters 
Single 
comparison 
Permutation 
test (p<0.05) 
𝜌 (p-value) 
Multiple 
comparison 
FDR test 
(𝛼<0.1) 
𝜌 (𝛼) 
Single 
comparison 
Permutation 
test (p<0.05) 
𝜌 (p-value) 
Multiple 
comparison 
FDR test 
(𝛼<0.1) 
𝜌 (𝛼) 
Single 
comparison 
Permutation 
test (p<0.05) 
𝜌 (p-value) 
Multiple 
comparison 
FDR test 
(𝛼<0.1) 
𝜌 (𝛼) 
Single 
comparison 
Permutation 
test (p<0.05) 
𝜌 (p-value) 
Multiple 
comparison 
FDR test 
(𝛼<0.1) 
𝜌 (𝛼) 
Single 
comparison 
Permutation 
test (p<0.05) 
𝜌 (p-value) 
Multiple 
comparison 
FDR test 
(𝛼<0.1) 
𝜌 (𝛼) 
Single 
comparison 
Permutation 
test (p<0.05) 
𝜌 (p-value) 
Multiple 
comparison 
FDR test 
(𝛼<0.1) 
𝜌 (𝛼) 
T_
p
ea
k 
Mean n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Heterogeneity 
(Std Dev) 
-0.90 
 (0.002) 
-0.90 
(0.022) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
25 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
75 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
P
ea
k 
Mean n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Heterogeneity 
(Std Dev) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
25 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
75 prct 
n.s. n.s. n.s. n.s. n.s n.s. 
0.74 
(0.021) 
n.s. 
0.64 
 (0.047) 
n.s. 
0.74 
(0.021) 
n.s. 
T_
ra
is
e 
Mean n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Heterogeneity 
(Std Dev) 
-0.86 
 (0.006) 
-0.86 
(0.066) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
25 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
75 prct -0.75 
 (0.019) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
T_
w
as
h
 
Mean n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Heterogeneity 
(Std Dev) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
25 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
75 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
M
TT
 
Mean 0.81  
(0.011) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Heterogeneity 
(Std Dev) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
25 prct 
n.s. n.s. n.s. n.s. n.s. n.s. 
-0.85 
(0.006) 
-0.85 
(0.077) 
-0.71 
(0.028) 
n.s. 
-0.85 
(0.006) 
-0.85 
(0.077) 
75 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
B
V
I (
A
U
C
) 
Mean 
n.s. n.s. 
0.71 
(0.029) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
Heterogeneity 
(Std Dev) 
-0.83 
 (0.008) 
-0.83 
(0.091) 
n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
25 prct n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
75 prct 
n.s. n.s. 
0.76  
(0.019) 
0.71 (0.029) n.s. n.s. 
0.80 
(0.011) 
n.s. n.s. 
0.80 
(0.011) 
n.s. n.s. 
Fig. 1  
Analysis of IL-17A-F+ IL-23R+ CD161+ CD4+ T  cells phenotypes in SF of PsA patients. Representative 
dot plots  showing the CD161+  T cells gated on T CD4+ cells, and the CD4+IL-17A-F+ and CD4+IL-
23R+  cells, gated on the CD161+ CD4+ T cells in the synovial fluid (SF) of psoriatic arthritis patients 
(PsA). (upper panel) and the frequencies of the distinct CD4+ T helper cells subsets in the SF of PsA 
patients (bottom panel). Data represented as mean ± SEM. Significance calculated by Student’s t 
test 
 
 
  
Fig.  2 
Representative single compartment recirculation model (gamma variate with its integral) for 
representing CEUS kinetics (upper panel). The correspondent parameters are reported both on the 
curve and with the abbreviations and formulas (bottom panel).  
  
 
 
  
Parameter Abbreviation Formula 
Time of the intensity curve to 
reach half of its maximum value 
T_raise 
𝑐𝑆𝐶𝑅(𝒑, 𝑇_𝑟𝑎𝑖𝑠𝑒) = 0.5 ∙ 𝑃𝑒𝑎𝑘 
0 < 𝑇_𝑟𝑎𝑖𝑠𝑒 < 𝑇_𝑝𝑒𝑎𝑘 
Maximum value of the intensity 
curve 
Peak max (𝑐𝑆𝐶𝑅(𝒑, 𝑡)) 
Time to reach the maximum 
value of the curve 
T_peak 𝑐𝑆𝐶𝑅(𝒑, 𝑇_𝑝𝑒𝑎𝑘)=Peak 
Time of the intensity curve to 
reduce to half of its maximum 
value 
T_wash 
𝑐𝑆𝐶𝑅(𝒑, 𝑇_𝑤𝑎𝑠ℎ) = 0.5 ∙ 𝑃𝑒𝑎𝑘 
𝑇_𝑝𝑒𝑎𝑘 < 𝑇_𝑤𝑎𝑠ℎ <100 
Mean transit time MTT 𝑀𝑇𝑇 = 𝑇_𝑤𝑎𝑠ℎ − 𝑇_𝑟𝑎𝑖𝑠𝑒 
Blood volume index (area under 
the curve) 
BVI (AUC) 𝐵𝑉𝐼 = ∫ 𝑐𝑆𝐶𝑅(𝒑, 𝑡)𝑑𝑡
100
0
 
Fig. 3  
Representative false-color parametric map of blood volume index (BVI) superimposed on the 
correspondent B-mode ultrasound image of the synovium (left panel). The distribution of BVI values 
is represented (central panel) with its statistical descriptors. The descriptors allow the identification 
of regions of low and high BVI on the B-mode ultrasound image of the synovium (right panel). 
 
